A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Eicosapentaenoic acid
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 19 Mar 2012 Results presented at the 76th Annual Scientific Meeting of the Japanese Circulation Society.
- 10 May 2011 Top-line results released in a Takeda and Pronova BioPharma media release.
- 10 May 2011 Primary endpoint 'Triglyceride-levels' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History